Abstract:Rituximab (RIT) is a mouse-human chimeric anti-CD20 monoclonal antibody that is one of the key drugs for the treatment of CD20-positive B cell non-Hodgkin lymphoma (B-NHL). Although RIT frequently causes infusion reactions (IR) during initial administration, there have been few reports about the frequency and risk factors for IR during re-administration of RIT to patients with recurrence. In this study, we investigated the frequency of clinically relevant IR (Grade ≥ 2) that occurred during re-administration o… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.